Fountzilas, Elena http://orcid.org/0000-0002-4884-2544
Apostolou, Paraskevi
Vasiliadis, Angelo V.
Aivazi, Dimitra
Saloustros, Emmanouil
Fostira, Florentia
Article History
Received: 29 May 2021
Accepted: 19 January 2022
First Online: 24 January 2022
Declarations
:
: EF: advisory role: LEO pharma. Speaker fees: Roche, Pfizer, AstraZeneca. Stock ownership: GENPREX INC, Deciphera Pharmaceuticals, Inc. Travel grant: Merck, Pfizer, and K.A.M Oncolo-gy/Hematology and DEMO. The rest of the authors declare they have no conflict of interest and have no substantial or indirect commercial finance incentive associated with publishing this article.
: The questionnaire and methodology for this study was approved by the bioethics committee of Euromedica General Clinic (CLI00489/16.3.2021).
: No non-human animal studies were carried out by the authors for this article.